Press Releases

 

Optima Study/HCC

  Date Title and Summary View
Aug 7, 2017
OPTIMA Study at Over 60% Patient Enrollment, DMC Provides Unanimous Recommendation to Continue Celsion Summarizes Regulatory Strategy for ThermoDox® LAWRENCEVILLE, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced that the independent Data Monitoring Committ...
Nov 30, 2016
LAWRENCEVILLE, N.J., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced that following a review of data from its multinational, randomized pivotal Phase III clinical study of ThermoDox® in combination with optimized radiofrequency ablation (RFA) for primary liver cancer (the OPTIMA Study), the study's Data Mo...
Jul 11, 2016
LAWRENCEVILLE, N.J., July 11, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced that its ongoing Phase III OPTIMA trial evaluating ThermoDox® in primary liver cancer, also known as hepatocellular carcinoma or HCC, was featured during an oral presentation at the 7th Asia-Pacific Primary Liver Cancer Expert (APPLE) Mee...
Jun 21, 2016
Ongoing Phase III Trial to Confirm Hypothesis That The Combination of Standardized Radio Frequency Ablation (sRFA) Plus Lyso-Thermosensitive Liposomal Doxorubicin (LTLD) May Substantially Increase Survival of Patients with HCC Compared to sRFA Alone LAWRENCEVILLE, N.J., June 21, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) toda...
Mar 7, 2016
LAWRENCEVILLE, N.J., March 7, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a fully-integrated oncology company focused on the development of a portfolio of innovative cancer treatments, today announced the launch of the OPTIMA Study in China. The Company held an Investigators' Meeting for the OPTIMA Study on March 5, 2016 in Shanghai, C...
Dec 16, 2015
LAWRENCEVILLE, N.J., Dec. 16, 2015 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced that it has received Clinical Trial Application (CTA) approval from the China Food and Drug Administration (CFDA) to conduct the ongoing Phase III OPTIMA Study at clinical sites in China. The OPTIMA Study is the Company's global pivotal, double-bli...
Nov 2, 2015
LAWRENCEVILLE, N.J., Nov. 2, 2015 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the presentation of data from the Company's HEAT Study, highlighting the curative potential for ThermoDox® plus optimized radiofrequency ablation (RFA) in intermediate primary liver cancer, also known as h...
Oct 6, 2015
LAWRENCEVILLE, N.J., Oct. 6, 2015 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the upcoming presentations of data supporting the Company's ongoing pivotal phase III OPTIMA Study of ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin in combination with o...
Sep 8, 2015
LAWRENCEVILLE, N.J., Sept. 8, 2015 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced highlights from presentations by three leading experts in the treatment of intermediate primary liver cancer, also known as hepatocellular carcinoma (HCC) and Celsion's pivotal Phase III OPTIMA Study of Thermo...
Nov 5, 2014
LAWRENCEVILLE, N.J., Nov. 5, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today that the Phase III OPTIMA Study was approved via Europe's centralized Voluntary Harmonization Procedure (VHP).  The approval allows Celsion to conduct the OPTIMA Study, its Phase III trial of ThermoDox® in primary liver cancer, also known as he...
Page:
1
NextLast
= add release to Briefcase
Share This